1. FTC v. Actavis, Inc. (2013, U.S. Supreme Court)

(Landmark “pay-for-delay” antitrust drug pricing case)

Facts:

• A brand-name drug company (Solvay Pharmaceuticals) held a patent.
• Generic manufacturers challenged it.
• Instead of competing, Solvay paid the generics to delay entry into the market.
• Result: consumers kept paying high monopoly prices.

Legal Issue:

Whether such “reverse payment settlements” violate antitrust laws.

Judgment:

• Supreme Court held: YES, they can violate antitrust law.
• Even if within patent settlement rights, large payments to delay competition must be scrutinized.

Legal Principle:

A patent does not automatically protect anti-competitive agreements that artificially maintain high drug prices.

Importance for overcharging litigation:

• Courts treat delayed generics as indirect consumer overcharging.
• Price inflation caused by blocking competition = actionable harm.

2. In re EpiPen (Mylan Pricing Litigation, U.S. Federal Courts)

(Excessive pricing + product bundling allegations)

Facts:

• Mylan raised the price of the EpiPen (epinephrine injector) dramatically over several years.
• Allegations included:
  • product bundling with pharmacy benefit managers,
  • exclusionary rebates,
  • lack of meaningful competition.

Legal Issue:

Whether price hikes and rebate structures constituted unlawful monopolization.

Outcome (procedural):

• Multiple class actions and state suits were filed.
• Many were settled without full trial findings of liability.

Legal Principle applied:

Courts focused on:

• monopoly power in essential medicines,
• whether price increases were tied to exclusionary conduct.

Importance:

• Even without direct “price cap violation,” systematic overpricing combined with market control can trigger liability.

3. In re Insulin Pricing Litigation (U.S. Multi-District Litigation)

(Modern insulin price inflation cases against Eli Lilly, Novo Nordisk, Sanofi)

Facts:

• Insulin prices increased drastically over a decade.
• Manufacturers were accused of:
  • coordinated pricing strategies,
  • rebate “kickback” systems with pharmacy benefit managers,
  • artificial list-price inflation.

Legal Issue:

Whether insulin pricing systems violated:

• antitrust laws,
• consumer protection statutes,
• RICO (racketeering) allegations in some claims.

Court Approach:

• Courts allowed many claims to proceed to discovery.
• Focus was on whether rebate structures distorted real competition.

Legal Principle:

Hidden pricing systems that distort market transparency can amount to unfair or deceptive trade practices.

Importance:

• Shows modern courts examine net pricing vs list pricing manipulation.

4. FTC v. AbbVie Inc. (Testosterone Replacement Drug Case, U.S. 2018 onward)

(Patent litigation abuse + “sham” settlements)

Facts:

• AbbVie filed multiple patent lawsuits against generic competitors.
• Allegations: lawsuits were weak and designed to delay generics.
• Settlements allegedly included compensation to keep generics out.

Legal Issue:

Whether litigation abuse was used to maintain high drug prices.

Judgment:

• Lower courts found some anticompetitive conduct but limited damages.
• Appeals courts narrowed liability.

Legal Principle:

“Sham litigation” used to block competition can constitute antitrust violation.

Importance:

• Direct link between legal strategy and artificial price maintenance.

5. Swasthya Adhikar Manch v. Union of India (Supreme Court of India, 2013–2017)

(Public Interest Litigation on drug pricing transparency)

Facts:

• Petition challenged:
  • high cost of essential medicines,
  • lack of transparency in clinical trials,
  • weak enforcement of price control mechanisms.

Legal Issue:

Whether the State had failed its constitutional duty under:

• Right to Health (Article 21),
• Drug Price Control Orders under Essential Commodities framework.

Judgment:

• Supreme Court emphasized:
  • access to affordable medicines is part of right to life and health.
• Directed better regulation and transparency in pricing mechanisms.

Legal Principle:

Essential medicines cannot be priced in a way that defeats constitutional healthcare rights.

Importance:

• India recognizes constitutional dimension of drug overpricing, not just consumer law.

6. All India Drug Action Network v. Union of India (Delhi High Court & related proceedings)

(Challenge to drug price control policy limitations)

Facts:

• NGOs challenged weak price regulation under Drug Price Control Orders (DPCO).
• Alleged that many essential medicines were left outside price control.

Legal Issue:

Whether government failed to enforce adequate price ceilings on essential drugs.

Court’s Approach:

• Courts examined:
  • scope of National Pharmaceutical Pricing Authority (NPPA),
  • selective price controls,
  • impact on public health access.

Legal Principle:

Regulatory discretion in pricing must be exercised to ensure availability of essential medicines at fair cost.

Importance:

• Reinforces that state inaction on drug pricing can itself be challenged as unlawful policy failure.

KEY LEGAL THEMES ACROSS THESE CASES

1. Monopoly Abuse

Drug companies controlling essential medicines may be liable if they exploit market dominance.

2. Artificial Price Inflation

Courts examine:

• list price vs net price
• rebate systems
• delayed generic entry

3. Consumer Harm Standard

Harm is not only overpayment but also:

• reduced access to medicines
• public health impact

4. Regulatory + Constitutional Dimension (India)

Drug pricing is tied to:

• right to health
• essential commodity regulation
• government duty to control prices

5. Evidence Standard

Courts require:

• proof of anti-competitive conduct OR regulatory violation
• not just “high prices alone” in most U.S. antitrust cases

CONCLUSION

Drug price overcharging litigation is rarely about “expensive medicine” alone. Courts generally require proof of:

• market manipulation (antitrust)
• regulatory violation (price control laws)
• or exclusion of competition (generic delay, rebate schemes)

Across jurisdictions, the strongest legal trend is:

High drug prices become unlawful only when they are tied to abuse of monopoly power, exclusion of competition, or violation of statutory pricing duties.